

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all previous versions and listings of claims in the application:

1-118. (canceled)

119. (Currently Amended) An isolated polypeptide having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:349;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:349, lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203044;  
~~— wherein the nucleic acid encoding said polypeptide is amplified in lung or colon cancer.~~

120. (Currently Amended) An isolated polypeptide having at least 85% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:349;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:349, lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203044;  
~~— wherein the nucleic acid encoding said polypeptide is amplified in lung or colon cancer.~~

121. (Currently Amended) An isolated polypeptide having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:349;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:349, lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203044;  
~~— wherein the nucleic acid encoding said polypeptide is amplified in lung or colon cancer.~~

122. (Currently Amended) An isolated polypeptide having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:349;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:349, lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203044;

~~— wherein the nucleic acid encoding said polypeptide is amplified in lung or colon cancer.~~

123. (Currently Amended) An isolated polypeptide having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:349;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:349, lacking its associated signal peptide; or
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203044;

~~— wherein the nucleic acid encoding said polypeptide is amplified in lung or colon cancer.~~

124. (Previously Presented) An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:349;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO:349, lacking its associated signal peptide; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203044.

125. (Previously Presented) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide of SEQ ID NO:349.

126. (Previously Presented) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide of SEQ ID NO:349, lacking its associated signal peptide.

127-128. (Cancelled)

129. (Previously Presented) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203044.

130. (Previously Presented) A chimeric polypeptide comprising a polypeptide according to Claim 124 fused to a heterologous polypeptide.

131. (Previously Presented) The chimeric polypeptide of Claim 130, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.